Zoetis Inc. (NYSE:ZTS) Shares Bought by World Investment Advisors

World Investment Advisors lifted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 13.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,793 shares of the company's stock after purchasing an additional 4,557 shares during the period. World Investment Advisors' holdings in Zoetis were worth $6,320,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of ZTS. Dunhill Financial LLC lifted its stake in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after buying an additional 75 shares in the last quarter. Atlantic Edge Private Wealth Management LLC increased its stake in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after buying an additional 140 shares in the last quarter. Rakuten Securities Inc. raised its holdings in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 166 shares during the period. Murphy & Mullick Capital Management Corp purchased a new position in shares of Zoetis in the fourth quarter valued at about $44,000. Finally, Quarry LP boosted its stake in shares of Zoetis by 45.9% in the third quarter. Quarry LP now owns 305 shares of the company's stock worth $60,000 after acquiring an additional 96 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock valued at $312,254 in the last three months. Company insiders own 0.16% of the company's stock.

Remove Ads

Zoetis Trading Down 1.8 %

NYSE:ZTS traded down $2.70 during midday trading on Monday, hitting $149.03. 4,263,169 shares of the company traded hands, compared to its average volume of 2,601,967. The firm has a market capitalization of $66.73 billion, a P/E ratio of 27.24, a P/E/G ratio of 2.78 and a beta of 0.92. The firm's fifty day moving average is $165.71 and its 200-day moving average is $173.26. Zoetis Inc. has a 12-month low of $144.07 and a 12-month high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.34%. Zoetis's payout ratio is 36.56%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Piper Sandler boosted their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Stifel Nicolaus reduced their target price on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Finally, Barclays boosted their target price on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.